Leinco Technologies

Anti-Human HLA-A, B, C (MHC Class I) - Purified in vivo GOLD™ Functional Grade

Product Code:
 
LEI-H263
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
IgG2a κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
W6/32
Regulatory Status:
 
RUO
Target Species:
  • Baboon
  • Bovine (Cattle)
  • Chimpanzee
  • Cynomolgus Monkey
  • Feline (cat)
  • Human
Applications:
  • Blocking
  • Flow Cytometry
  • Immunohistochemistry- Frozen Section (IHC-F)
  • Immunoprecipitation (IP)
  • In Vivo Assay
  • Spatial Biology
  • Western Blot (WB)
Shipping:
 
2-8°C
Storage:
 
This antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at - 20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-H263-1.0mg1.0 mg£175.00
Quantity:
LEI-H263-5.0mg5.0 mg£380.00
Quantity:
LEI-H263-25mg25 mg£1,014.00
Quantity:
LEI-H263-50mg50 mg£1,556.00
Quantity:
LEI-H263-100mg100 mg£2,159.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Antigen Distribution:
HLA-A, -B, and -C are ubiquitously expressed on nucleated cells.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
in vivo GOLD™, Purified in vivo Functional Grade
Format:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Human tonsil cell membrane
Long Description:
HLA antibody, clone W6/32, recognizes the major histocompatibility complex (MHC) class I molecules human leukocyte antigen (HLA)-A, HLA-B, and HLA-C. MHC class I is ubiquitously expressed on the cell surface of nucleated cells and consists of a 45-kDa type I transmembrane glycoprotein (α-chain or heavy chain) and a 12-kDa soluble protein (β2-microglobulin, β2M)1,2. The α-chain consists of three domains (α1, α2, and α3)3. α1 and α2 form the closed antigen-binding groove and bind to 8-10 aa peptides derived from cytosolic antigens4-6. β2M noncovalently associates with α3, which is essential for MHC stability. MHC class I plays a critical role in the adaptive immune response by presenting endogenous antigens to cytotoxic CD8 T cells. MHC class I molecules can also present exogenous antigens to CD8 T cells via a process known as cross-presentation7. The T cell receptor (TCR)/CD3 complex of CD8 T cells interacts with peptide-MHC class I, which induces CD8 T cell activation and subsequent cell-killing. CD8 molecules also bind to MHC class I, which helps augment TCR signaling8. In contrast to CD8 T cells, MHC class I is an inhibitory ligand for natural killer (NK) cells, promoting self tolerance9. MHC class I also contributes to the positive selection of CD8 T cells and NK cell specificity10,11.
NCBI Gene:
3105
Purity:
?95% monomer by analytical SEC, >95% by SDS Page
Target:
HLA-A,B,C

References

1. Mitaksov V & Fremont DH. (2006) J Biol Chem. 281(15):10618-25 2. Wieczorek M, et al. (2017) Front Immunol. 8:292 3. Jones EY. (1997) Curr Opin Immunol. 9(1):75-9 4. Matsumura M, et al. (1992) Science. 257:927?34.10.1126/science.1323878 5. Bouvier M & Wiley DC. (1994) Science. 265:398?402.10.1126/science.8023162 6. Zacharias M & Springer S. (2004) Biophys J. 87:2203?14.10.1529/biophysj.104.044743 7. Cruz FM, et al (2017) Annu Rev Immunol. 35:149-176 8. Artyomov MN, et al (2010) Proc Natl Acad Sci USA. 107(39):16916-16921 9. Orr MT & Lanier LL. (2010) Cell. 142(6):847-856 10. Raulet DH. (1994) Adv Immunol. 55:381-421 11. Salcedo M & Ljunggren HG. (1996) Chem Immunol. 64:44-58